NASDAQ · Analyst Forecast

Benitec Biopharma Inc. (BNTC) Stock Forecast & Price Target

$8.27 NASDAQ: BNTC Market Cap $288.53M

Price as of Nov 18, 2026 close · Analyst estimates retrieved Nov 16, 2026 · Source: Financial Modeling Prep (analyst estimates) (methodology)

Revenue and earnings estimates published by analysts covering Benitec Biopharma Inc. (BNTC), and the range of their price targets. Everything on this page is a forecast made by other people — DeltaScreener does not produce estimates or targets of its own.

For Benitec Biopharma Inc., analysts forecast revenue rising from $25.43M in 2026 to $221.79M in 2031; the average estimate for 2031 earnings per share is $0.90; 6 analysts contribute to these figures. These are forecasts published by analysts, not results.

Analyst price targets

MeasureValue
Current priceWhat the share trades at now.$8.27
Consensus targetThe average of the price targets analysts have published.$17.00
Median targetThe middle target, less affected by a single outlier.$17.00
Highest targetThe most optimistic published target.$20.00
Lowest targetThe most pessimistic published target.$14.00
Difference from priceHow far the consensus target sits from today’s price.+105.6%

A price target is one analyst's forecast of where a share might trade, usually over twelve months. Targets are frequently revised, they disagree with each other, and they are not a measure of what a company is worth.

Revenue forecast (USD)

The spread between low and high is how far analysts disagree, which is usually a better guide than the average alone.

YearLowAverageHighAnalysts
2026$25.43M$25.43M$25.43M6
2027$21.86M$21.86M$21.86M6
2028$17.77M$17.77M$17.77M3
2029$131.05M$131.05M$131.05M3
2030$55.33M$55.33M$55.33M1
2031$221.79M$221.79M$221.79M2

Earnings per share forecast

YearLowAverageHighAnalysts
2026−$1.07−$0.98−$0.926
2027−$1.32−$1.22−$1.046
2028−$1.57−$1.49−$1.393
2029−$1.43−$1.37−$1.313
2030−$0.98−$0.98−$0.981
2031$0.90$0.90$0.902

Benitec Biopharma Inc. (BNTC) forecast — frequently asked questions

What is the analyst price target for Benitec Biopharma Inc.?

Analysts covering Benitec Biopharma Inc. (BNTC) have a consensus price target of $17.00, 105.6% above the current price of $8.27. Published targets range from $14.00 to $20.00. A price target is a forecast, not a measure of value, and targets are revised often.

What are analysts forecasting for Benitec Biopharma Inc.'s earnings?

The average analyst estimate for Benitec Biopharma Inc. (BNTC) earnings per share in 2031 is 0.90, with individual estimates between 0.90 and 0.90.

How much revenue is Benitec Biopharma Inc. expected to make?

Analysts forecast Benitec Biopharma Inc. (BNTC) revenue of $221.79M in 2031, based on 2 published estimates.

How many analysts cover BNTC?

6 analysts contribute estimates for Benitec Biopharma Inc. (BNTC). Thin coverage makes an average less reliable.

Analyst forecasts for other Biotechnology stocks

VRTX forecastREGN forecastMRNA forecastRVMD forecastROIV forecastINSM forecastUTHR forecastINCY forecastALNY forecastASND forecastAll Biotechnology stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.